Free Trial

HC Wainwright's Rating of Zenas BioPharma on 9/30/2026

On September 30, 2026, HC Wainwright updated its outlook on Zenas BioPharma (NASDAQ:ZBIO) with the action "Reiterated Rating", keeping a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from HC Wainwright

DateCompanyAction
10/14/2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Reiterated Rating
10/14/2026
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
Reiterated Rating
10/14/2026
Alector, Inc. stock logo
ALEC
Alector
Boost Price Target
10/14/2026
Evotec AG stock logo
EVO
Evotec
Reiterated Rating
10/14/2026
Integra Resources Corp. stock logo
ITRG
Integra Resources
Reiterated Rating
10/14/2026
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
Reiterated Rating
More Ratings From HC Wainwright